Bain Capital Life Sciences Investors, LLC's Form 4 filing
Olema Pharmaceuticals, Inc. (OLMA) · filed Jan 13, 2025
- Accession no.
- 0000950170-25-004870
- Filed
- Jan 13, 2025, 4:34 PM ET
- Trade date
- Jan 8-10, 2025
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market purchases total $1.73M. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Bain Capital Life Sciences Investors, LLCCIK 0001703031 | 10% Owner |
| Bain Capital Life Sciences IV General Partner, LLCCIK 0001996931 | 10% Owner |
| Bain Capital Life Sciences Fund IV, L.P.CIK 0001996979 | 10% Owner |
| Bain Capital Life Sciences Opportunities IV, L.P.CIK 0002015553 | 10% Owner |
| Bain Capital Life Sciences Opportunities IV GP, LLCCIK 0002015657 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 8, 2025 | Common Stock | PPurchaseAcquired | +300,000 | $5.76 | +$1,727,370 | 7,800,000 | Indirect | |
| Jan 10, 2025 | Common Stock | JOtherDisposed | −3,500,000 | – | – | 4,300,000 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 10, 2025 | Common Stock | JOtherAcquired | +3,500,000 | – | – | 3,500,000 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.